# Functional Enrichment Analysis of Rare Mutations in Patients with Brain Arteriovenous Malformations

**Authors:** Elena Zholdybayeva, Ayazhan Bekbayeva, Karashash Menlibayeva, Alua Gusmaulemova, Botakoz Kurentay, Bekbolat Tynysbekov, Almas Auganov, Ilyas Akhmetollayev, Chingiz Nurimanov

PMC · DOI: 10.3390/biomedicines13061451 · Biomedicines · 2025-06-12

## TL;DR

This study identifies potential genetic factors linked to brain arteriovenous malformations by analyzing rare mutations in patients from Kazakhstan.

## Contribution

The study provides new insights into candidate genes and biological pathways involved in the development of brain arteriovenous malformations.

## Key findings

- Candidate genes like COL3A1, CTNNB1, and ERBB2 were identified as potentially linked to brain AVM development.
- Genes such as SLIT3, SMO, and MAPK3 were found to have damaging mutations affecting vasculogenesis and angiogenesis.
- Defects in genes related to ciliary structure and function may play a critical role in the pathogenesis of brain AVMs.

## Abstract

Background/Objectives: Brain arteriovenous malformations (bAVMs) are rare vascular anomalies characterized by direct connections between arteries and veins, bypassing the capillary network. This study aimed to identify potential genetic factors contributing to the development of sporadic bAVMs. Methods: Three patients (AVM1–3) from Kazakhstan who underwent microsurgical resection at the National Centre for Neurosurgery (NCN) in Astana, Kazakhstan, were analyzed. Brain AVMs were diagnosed using magnetic resonance imaging (MRI). Genomic DNA was isolated from whole venous blood samples, and whole-exome sequencing was performed on the NovaSeq 6000 platform (Illumina). Variants were filtered according to standard bioinformatics protocols, and candidate gene prioritization was conducted using the ToppGene tool. Results: In silico analysis further revealed candidate genes likely associated with lesion development, including COL3A1, CTNNB1, LAMA1, NPHP3, SLIT2, SLIT3, SMO, MAPK3, LRRK2, TTN, ERBB2, PARD3, and OBSL1. It is essential to focus on the genetic variants affecting the following prioritized genes: ERBB2, SLIT3, SMO, MAPK3, and TTN. Mutations in these genes were predicted to be “damaging”. Most of these genes are involved in signaling pathways that control vasculogenesis and angiogenesis. Conclusions: Defects in genes associated with ciliary structure and function may be critical to the pathogenesis of brain AVMs. These findings provide valuable insights into the molecular underpinnings of bAVM development, emphasizing key biological pathways and potential candidate genes. Further research is needed to establish robust correlations between specific genetic mutations and clinical phenotypes, which could ultimately inform the development of improved diagnostic, therapeutic, and prognostic approaches.

## Linked entities

- **Genes:** COL3A1 (collagen type III alpha 1 chain) [NCBI Gene 1281], CTNNB1 (catenin beta 1) [NCBI Gene 1499], LAMA1 (laminin subunit alpha 1) [NCBI Gene 284217], NPHP3 (nephrocystin 3) [NCBI Gene 27031], SLIT2 (slit guidance ligand 2) [NCBI Gene 9353], SLIT3 (slit guidance ligand 3) [NCBI Gene 6586], SMO (smoothened, frizzled class receptor) [NCBI Gene 6608], MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595], LRRK2 (leucine rich repeat kinase 2) [NCBI Gene 120892], TTN (titin) [NCBI Gene 7273], ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064], PARD3 (par-3 family cell polarity regulator) [NCBI Gene 56288], OBSL1 (obscurin like cytoskeletal adaptor 1) [NCBI Gene 23363]

## Full-text entities

- **Genes:** LAMA1 (laminin subunit alpha 1) [NCBI Gene 284217] {aka LAMA, PTBHS, S-LAM-alpha}, TTN (titin) [NCBI Gene 7273] {aka CMD1G, CMH9, CMPD4, CMYO5, CMYP5, EOMFC}, LRRK2 (leucine rich repeat kinase 2) [NCBI Gene 120892] {aka AURA17, DARDARIN, PARK8, RIPK7, ROCO2}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595] {aka ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1}, COL3A1 (collagen type III alpha 1 chain) [NCBI Gene 1281] {aka EDS4A, EDSVASC, PMGEDSV}, PARD3 (par-3 family cell polarity regulator) [NCBI Gene 56288] {aka ASIP, Baz, PAR3, PAR3alpha, PARD-3, PARD3A}, SLIT3 (slit guidance ligand 3) [NCBI Gene 6586] {aka MEGF5, SLIL2, SLIT1, Slit-3, slit2}, SLIT2 (slit guidance ligand 2) [NCBI Gene 9353] {aka SLIL3, Slit-2}, NPHP3 (nephrocystin 3) [NCBI Gene 27031] {aka CFAP31, MKS7, NPH3, RHPD, RHPD1, SLSN3}, SMO (smoothened, frizzled class receptor) [NCBI Gene 6608] {aka CRJS, FZD11, Gx, PHLS, SMOH}, OBSL1 (obscurin like cytoskeletal adaptor 1) [NCBI Gene 23363]
- **Diseases:** AVM1-3 (MESH:C537153), vascular anomalies (MESH:D020785), Brain Arteriovenous Malformations (MESH:D002538), Brain AVMs (MESH:C564254), lesion (MESH:D009059)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12191260/full.md

## Figures

14 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12191260/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12191260/full.md

---
Source: https://tomesphere.com/paper/PMC12191260